Arrhythmias & electrophysiology
Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia
Authors' conclusion
For patients with catecholaminergic polymorphic ventricular tachycardia, adding flecainide to beta-blocker therapy was associated with a lower incidence of AEs in the overall cohort, in symptomatic patients, and particularly in patients with breakthrough AEs while on beta-blocker therapy.
Study context
- Population
- Patients with clinical or genetic diagnosis of catecholaminergic polymorphic VT on beta-blockers
- Participants
- 247 patients
- Exposure
- Flecainide added to beta-blockers vs beta-blockers alone
- Outcome
- Arrhythmic events:
- SCD
- Sudden cardiac arrest
- Appropriate ICD shock
- Arrhythmic syncope
Methodological detailsmulticentre, 2 international registries
- Multicentre
- 2 international registries
Main finding
As reported in the abstract
AEs (SCD, sudden cardiac arrest, appropriate ICD shock, arrhythmic syncope)
AEs On-flecainide 38 · Pre-flecainide 58
Annual event rate
Median follow-up On-flecainide 2.9 years (IQR 1.0-6.0) · Pre-flecainide 2.1 years (IQR 0.4-7.2)
Observational data: associations, not effects.
Further findings
| Outcome | IRR (95% CI) | P value | |
|---|---|---|---|
| AEs in patients symptomatic before diagnosis or pre-flecainide (subgroup, n=167) | 0.49 (0.31–0.77) | P = 0.002 | |
| AEs in patients with ≥1 AE on beta-blocker (subgroup, n=41) | 0.25 (0.14–0.45) | P < 0.001 | |
| 0.10.31310Incidence rate ratio (log scale) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →